Uptake, outcomes, and costs of implementing non-invasive prenatal testing for Down's syndrome into NHS maternity care: Prospective cohort study in eight diverse maternity units

BMJ (Online)

Volumn 354, Issue , 2016, Pages

  Chitty, Lyn S ^a,b   Wright, David ^c   Hill, Melissa ^a   Verhoef, Talitha I ^d   Daley, Rebecca ^b   Lewis, Celine ^a,b   Mason, Sarah ^b   McKay, Fiona ^b   Jenkins, Lucy ^b   Howarth, Abigail ^b   Cameron, Louise ^e   McEwan, Alec ^f   Fisher, Jane ^g   Kroese, Mark ^e   Morris, Stephen ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c UNIVERSITY OF PLYMOUTH   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e PHG FOUNDATION   (United Kingdom)

^f NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^g Antenatal Results and Choices (ARC)   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; AMNIOCENTESIS; ARTICLE; COHORT ANALYSIS; COST BENEFIT ANALYSIS; DOWN SYNDROME; FEMALE; FETUS DEATH; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HUMAN; LIVE BIRTH; MATERNAL CARE; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PRENATAL SCREENING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SPONTANEOUS ABORTION; UNITED KINGDOM; CLINICAL TRIAL; ECONOMICS; EPIDEMIOLOGY; GENETIC SCREENING; GENETICS; MATERNAL AGE; MULTICENTER STUDY; PATIENT ATTITUDE; PREGNANCY; PRENATAL DIAGNOSIS; PROCEDURES; SECOND TRIMESTER PREGNANCY; STATISTICS AND NUMERICAL DATA; UTILIZATION;

COST-BENEFIT ANALYSIS; DOWN SYNDROME; FEMALE; GENETIC TESTING; HUMANS; MATERNAL AGE; PATIENT ACCEPTANCE OF HEALTH CARE; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; PROSPECTIVE STUDIES; UNITED KINGDOM;

EID: 84978225119     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i3426     Document Type: Article

References (46)

1. Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 2015;45:249-66. doi:10.1002/uog.14791.
2. Norton ME, Jacobsson B, Swamy GK, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med 2015;372:1589-97. doi:10.1056/NEJMoa1407349.
3. Zhang H, Gao Y, Jiang F, et al. Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146,958 pregnancies. Ultrasound Obstet Gynecol 2015;45:530-8. doi:10.1002/uog.14792.
4. Warsof SL, Larion S, Abuhamad AZ. Overview of the impact of noninvasive prenatal testing on diagnostic procedures. Prenat Diagn 2015;35:972-9. doi:10.1002/pd.4601.
5. Minear MA, Lewis C, Pradhan S, Chandrasekharan S. Global perspectives on clinical adoption of NIPT. Prenat Diagn 2015;35:959-67. doi:10.1002/pd.4637.
6. Tischler R, Hudgins L, Blumenfeld YJ, Greely HT, Ormond KE. Noninvasive prenatal diagnosis: pregnant women's interest and expected uptake. Prenat Diagn 2011;31:1292-9. doi:10.1002/pd.2888.
7. Chetty S, Garabedian MJ, Norton ME. Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening. Prenat Diagn 2013;33:542-6. doi:10.1002/pd.4125.
8. Lewis C, Hill M, Silcock C, Daley R, Chitty LS. Non-invasive prenatal testing for trisomy 21: a cross-sectional survey of service users' views and likely uptake. BJOG 2014;121:582-94. doi:10.1111/1471-0528.12579.
9. Morris S, Karlsen S, Chung N, Hill M, Chitty LS. Model-based analysis of costs and outcomes of non-invasive prenatal testing for Down's syndrome using cell free fetal DNA in the UK National Health Service. PLoS One 2014;9:e93559. doi:10.1371/journal. pone.0093559.
10. Cuckle H, Benn P, Pergament E. Maternal cfDNA screening for Down syndrome-a cost sensitivity analysis. Prenat Diagn 2013;33:636-42. doi:10.1002/pd.4157.
11. Ayres AC, Whitty JA, Ellwood DA. A cost-efectiveness analysis comparing diferent strategies to implement noninvasive prenatal testing into a Down syndrome screening program. Aust N Z J Obstet Gynaecol 2014;54:412-7. doi:10.1111/ajo.12223.
12. Beulen L, Grutters JP, Faas BH, Feenstra I, van Vugt JM, Bekker MN. The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-efectiveness analysis. Eur J Obstet Gynecol Reprod Biol 2014;182:53-61. doi:10.1016/j. ejogrb.2014.08.028.
13. Cuckle H, Benn P, Pergament E. Maternal cfDNA screening for Down syndrome--a cost sensitivity analysis. Prenat Diagn 2013;33:636-42. doi:10.1002/pd.4157.
14. Garfeld SS, Armstrong SO. Clinical and cost consequences of incorporating a novel non-invasive prenatal test into the diagnostic pathway for fetal trisomies. J Managed Care Med 2012;15:34-41.
15. Neyt M, Hulstaert F, Gyselaers W. Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis. BMJ Open 2014;4:e005922. doi:10.1136/bmjopen-2014-005922.
16. Ohno M, Caughey A. The role of noninvasive prenatal testing as a diagnostic versus a screening tool-a cost-efectiveness analysis. Prenat Diagn 2013;33:630-5. doi:10.1002/pd.4156.
17. Okun N, Teitelbaum M, Huang T, Dewa CS, Hoch JS. The price of performance: a cost and performance analysis of the implementation of cell-free fetal DNA testing for Down syndrome in Ontario, Canada. Prenat Diagn 2014;34:350-6. doi:10.1002/pd.4311.
18. O'Leary P, Maxwell S, Murch A, Hendrie D. Prenatal screening for Down syndrome in Australia: costs and benefts of current and novel screening strategies. Aust N Z J Obstet Gynaecol 2013;53:425-33. doi:10.1111/ajo.12136.
19. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011;13:913-20. doi:10.1097/GIM.0b013e3182368a0e.
20. Song K, Musci TJ, Caughey AB. Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population. J Matern Fetal Neonatal Med 2013;26:1180-5. doi:10.3109/14767058.2013.770464.
21. Wald NJ, Bestwick J P. Incorporating DNA sequencing into current prenatal screening practice for Down's syndrome. PLoS One 2013;8:e58732. doi:10.1371/journal.pone.0058732.
22. Walker BS, Jackson BR, LaGrave D, Ashwood ER, Schmidt RL. A cost-efectiveness analysis of cell free DNA as a replacement for serum screening for Down syndrome. Prenat Diagn 2015;35:440-6. doi:10.1002/pd.4511.
23. Gil MM, Giunta G, Macalli EA, Poon LC, Nicolaides KHUK. UK NHS pilot study on cell-free DNA testing in screening for fetal trisomies: factors afecting uptake. Ultrasound Obstet Gynecol 2015;45:67-73. doi:10.1002/uog.14683.
24. Gil MM, Revello R, Poon LC, Akolekar R, Nicolaides KH. Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results from frst-trimester combined test. Ultrasound Obstet Gynecol 2016;47:45-52. doi:10.1002/ uog.15783.
25. Public Health England. Down's syndrome screening: quality assurance support service. 2014. fetalanomaly.screening.nhs.uk/dqass.
26. American College of Obstetricians and Gynecologists. Committee Opinion No. 640: Cell-free DNA screening for fetal aneuploidy. Obstet Gynecol 2015;126:e31-7. doi:10.1097/AOG.0000000000001051.
27. Langlois S, Brock JA, Wilson RD, et al. Genetics Committee. Current status in non-invasive prenatal detection of Down syndrome, trisomy 18, and trisomy 13 using cell-free DNA in maternal plasma. J Obstet Gynaecol Can 2013;35:177-83. doi:10.1016/S1701-2163(15)31025-2.
28. Gregg AR, Gross SJ, Best RG, et al. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genet Med 2013;15:395-8. doi:10.1038/gim.2013.29.
29. Benn P, Borrell A, Chiu RWK, et al. Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn 2015;35:725-34. doi:10.1002/pd.4608.
30. Royal College of Obsetricians and Gynaecologists. Non-invasive prenatal testing for chromosomal abnormality using maternal plasma DNA (Scientifc Impact Paper No. 15). 2014. https://www.rcog.org.uk/ globalassets/documents/guidelines/sip-15-04032014.pdf.
31. Cuckle H, Benn P, Pergament E. Cell-free DNA screening for fetal aneuploidy as a clinical service. Clin Biochem 2015;48:932-41. doi:10.1016/j.clinbiochem.2015.02.011.
32. Hill M, Wright D, Daley R, et al. Evaluation of non-invasive prenatal testing (NIPT) for aneuploidy in an NHS setting: a reliable accurate prenatal non-invasive diagnosis (RAPID) protocol. BMC Pregnancy Childbirth 2014;14:229-38. doi:10.1186/1471-2393-14-229.
33. Lewis C, Silcock C, Chitty LS. Non-invasive prenatal testing for Down's syndrome: pregnant women's views and likely uptake. Public Health Genomics 2013;16:223-32. doi:10.1159/000353523.
34. Lo KK, Boustred C, Chitty LS, Plagnol V. RAPIDR: an analysis package for non-invasive prenatal testing of aneuploidy. Bioinformatics 2014;30:2965-7. doi:10.1093/bioinformatics/btu419.
35. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. NICE, 2014 (available from https://www.nice. org.uk/article/pmg20/chapter/glossary#costconsequences-analysis).
36. Tabor A, Alfrevic Z. Update on procedure-related risks for prenatal diagnosis techniques. Fetal Diagn Ther 2010;27:1-7. doi:10.1159/000271995.
37. Fetal Anomaly Screening Programme NHS. Decision planning tool. 2012. http://webarchive.nationalarchives.gov.uk/20150408175925/ http://fetalanomaly.screening.nhs.uk/professionalresources.
38. Curtis L. Unit costs of health and social care 2013. Personal Social Services Research Unit, University of Kent, 2013 (available from www. pssru.ac.uk/project-pages/unit-costs/2013/).
39. Department of Health. NHS reference costs 2012 to 2013. 2013 (updates 2015). www.gov.uk/government/publications/ nhs-reference-costs-2012-to-2013.
40. Ofce of National Statistics. Statistical Bulletin: Births in England and Wales, 2013. 2014. http://www.ons.gov.uk/ons/ dcp171778-371129.pdf.
41. Wax JR, Cartin A, Chard R, Lucas FL, Pinette MG. Noninvasive prenatal testing: impact on genetic counseling, invasive prenatal diagnosis, and trisomy 21 detection. J Clin Ultrasound 2015;43:1-6.
42. Lewis C, Hill M, Skirton H, Chitty LS. Development and validation of a measure of informed choice for women undergoing non-invasive prenatal testing for aneuploidy. Eur J Hum Genet 2016;24:809-16. doi:10.1038/ejhg.2015.207.
43. Johnson J, Pastuck M, Metcalfe A, et al. First-trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell-free DNA. Prenat Diagn 2013;33:1044-9. doi:10.1002/pd.4194.
44. Hill M, Johnson JA, Langlois S, et al. Preferences for prenatal tests for Down syndrome: an international comparison of the views of pregnant women and health professionals. Eur J Hum Genet 2016;24:968-75. doi:10.1038/ejhg.2015.249.
45. Wagner P, Sonek J, Hoopmann M, Abele H, Kagan KO. First-trimester screening for trisomy 18, 13, triploidy and Turner syndrome by a detailed early anomaly scan. Ultrasound Obstet Gynecol 2015; [Epub ahead of print]. doi:10.1002/uog.15829.
46. Petersen OB, Vogel I, Ekelund C, Hyett J, Tabor A. Danish Fetal Medicine Study Group Danish Clinical Genetics Study Group. Potential diagnostic consequences of applying non-invasive prenatal testing: population-based study from a county with existing frst-trimester screening. Ultrasound Obstet Gynecol 2014;43:265-71. doi:10.1002/ uog.13270.